PCA3 Reference Set Application: Arul Chinnaiyan (2020)

Abbreviated Name
PCA3 Ref Set App: Chinnaiyan (2020)
Lead Investigator
Chinnaiyan, Arul M.University of Michigan
Coordinating Investigator
Feng, Ziding Fred Hutchinson Cancer Center
Involved Investigators


No abstract availalbe.


Biopsy-naïve men provided post-digital rectal examination (DRE) urine prior to biopsy. MPS was calculated using the validated, locked multivariable model including only serum PSA, urinary PCA3, and urinary TMPRSS2:ERG. The MPS threshold approximating 95% sensitivity for GG ≥2 cancer was identified in a training cohort, and performance was measured in two external validation cohorts. We assessed the (i) overall biopsy-referral population and (ii) population meeting guideline-based testing criteria (ie, PSA 3-10; or PSA <3 with suspicious DRE).

Analytic Method

No analytic method available.


The MyProstateScore (MPS) test was validated for improved detection of clinically-significant (Grade Group [GG] ≥2) prostate cancer relative to PSA-based risk calculators. We sought to validate an optimal MPS threshold for clinical use in ruling-out GG ≥2 cancer in men referred for biopsy.



  • No biomarkers available at this time for this protocol.

Data Collections

  • No data collections available at this time for this protocol.
 Team Project
Start Date
Jan 1 2020
Finish Date
Oct 20 2020
Protocol ID
Protocol Type
Field of Research
Collaborative Group
Prostate and Urologic Cancers Research Group
Cancer Types
  • Malignant neoplasm of prostate

Associated Forms